Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:33:57.339Z.
Consensus retrieved: 2026-10-06T15:56:22.878Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:33:57.339Z.
Quote observation: 2026-10-06T17:29:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 87d00981f6afc2d6fb42b8babadf75d30967326f42a5e12d4c63051d6ceded83
Forward PE Ratio (N/A) = Dated Quote Price ($7.93) / Consensus Forward EPS ($-4.57)
FORWARD PE RATIO
N/A
Atrium Therapeutics, Inc.
Market Cap
$135.65M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | $135.65M | N/A |
| Freenome, Inc. (FRNM)vs › | $135.08M | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.65M | N/A |
| Organigram Global Inc. (OGI)vs › | $133.76M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $133.33M | N/A |
| LifeMD, Inc. (LFMD)vs › | $133.24M | N/A |
| Alpha Cognition Inc (ACOG)vs › | $138.31M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $132.64M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 6.96 |
| Immuneering Corporation (IMRX)vs › | $140.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.93, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.57 | $-5.05 – $-4.10 | 2 | n/m |
| 2027-12-31 | $-7.10 | $-7.14 – $-7.05 | 2 | n/m |
| 2028-12-31 | $-6.53 | $-6.76 – $-6.31 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
